ArticleJournal of inflammation research2026
Integrating Preoperative Preserved Ratio Impaired Spirometry and Inflammatory Markers to Predict Postoperative Complications and Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune exhaustion in esophageal cancer: interferon pathway dysregulation and neoadjuvant therapy response.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe postoperative complications (SPCs) adversely affect outcomes in esophageal squamous cell carcinoma (ESCC) following neoadjuvant therapy. The prognostic significance of preserved ratio impaired spirometry (PRISm) and inflammation-based biomarkers such as the systemic inflammation response index (SIRI) and lymphocyte-to-monocyte ratio (LMR) remains unclear. Methods: We retrospectively analyzed 224 ESCC patients who underwent esophagectomy after neoadjuvant therapy. PRISm was defined by FEV Results: PRISm and decreased SIRI independently predicted higher SPC risk (p < 0.05). The SPC nomogram demonstrated good discrimination (AUC = 0.726). PRISm was also associated with significantly worse OS and RFS (p < 0.001). Elevated SIRI and low LMR correlated with poor long-term outcomes. OS and RFS nomograms showed good calibration and outperformed TNM staging in clinical utility. Conclusion: PRISm and systemic inflammatory markers are independent predictors of complications and prognosis in ESCC after neoadjuvant therapy. The proposed nomograms offer practical tools for individualized preoperative risk stratification and may support tailored perioperative management, especially in older or high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.